FR3112684B1 - Composés pour le traitement de l’hémophilie - Google Patents

Composés pour le traitement de l’hémophilie Download PDF

Info

Publication number
FR3112684B1
FR3112684B1 FR2007806A FR2007806A FR3112684B1 FR 3112684 B1 FR3112684 B1 FR 3112684B1 FR 2007806 A FR2007806 A FR 2007806A FR 2007806 A FR2007806 A FR 2007806A FR 3112684 B1 FR3112684 B1 FR 3112684B1
Authority
FR
France
Prior art keywords
hemophilia
treatment
compounds
compound
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2007806A
Other languages
English (en)
Other versions
FR3112684A1 (fr
Inventor
Aline Thomas
Marie-Claire Dagher
Muriel Jourdan
Romain Navarro
Benoît Polack
Raphael Marlu
Landry Seyve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Polytechnique de Grenoble
Universite Grenoble Alpes
Centre Hospitalier Universitaire Grenoble Alpes
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Polytechnique de Grenoble
Universite Grenoble Alpes
Centre Hospitalier Universitaire Grenoble Alpes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2007806A priority Critical patent/FR3112684B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Polytechnique de Grenoble, Universite Grenoble Alpes, Centre Hospitalier Universitaire Grenoble Alpes filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CN202180065227.2A priority patent/CN116710080A/zh
Priority to CA3186258A priority patent/CA3186258A1/fr
Priority to US18/016,946 priority patent/US20230346727A1/en
Priority to EP21742857.2A priority patent/EP4185281A1/fr
Priority to PCT/EP2021/070656 priority patent/WO2022018256A1/fr
Priority to JP2023504745A priority patent/JP2024511910A/ja
Publication of FR3112684A1 publication Critical patent/FR3112684A1/fr
Application granted granted Critical
Publication of FR3112684B1 publication Critical patent/FR3112684B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

L’invention concerne un composé de formule générale (I), ou l’un de ses sels pharmaceutiquement acceptables, pour son utilisation pour le traitement de l’hémophilie chez un sujet, en particulier pour la restauration de la coagulation dans le plasma d’un sujet atteint d’hémophilie, ce composé étant avantageusement administrable par voie orale : [Chem 1] .
FR2007806A 2020-07-24 2020-07-24 Composés pour le traitement de l’hémophilie Active FR3112684B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR2007806A FR3112684B1 (fr) 2020-07-24 2020-07-24 Composés pour le traitement de l’hémophilie
CA3186258A CA3186258A1 (fr) 2020-07-24 2021-07-23 Composes pour le traitement de l'hemophilie
US18/016,946 US20230346727A1 (en) 2020-07-24 2021-07-23 Compounds for the treatment of hemophilia
EP21742857.2A EP4185281A1 (fr) 2020-07-24 2021-07-23 Composés pour le traitement de l'hémophilie
CN202180065227.2A CN116710080A (zh) 2020-07-24 2021-07-23 用于治疗血友病的化合物
PCT/EP2021/070656 WO2022018256A1 (fr) 2020-07-24 2021-07-23 Composés pour le traitement de l'hémophilie
JP2023504745A JP2024511910A (ja) 2020-07-24 2021-07-23 血友病の治療のための化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2007806 2020-07-24
FR2007806A FR3112684B1 (fr) 2020-07-24 2020-07-24 Composés pour le traitement de l’hémophilie

Publications (2)

Publication Number Publication Date
FR3112684A1 FR3112684A1 (fr) 2022-01-28
FR3112684B1 true FR3112684B1 (fr) 2022-08-12

Family

ID=73138945

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2007806A Active FR3112684B1 (fr) 2020-07-24 2020-07-24 Composés pour le traitement de l’hémophilie

Country Status (7)

Country Link
US (1) US20230346727A1 (fr)
EP (1) EP4185281A1 (fr)
JP (1) JP2024511910A (fr)
CN (1) CN116710080A (fr)
CA (1) CA3186258A1 (fr)
FR (1) FR3112684B1 (fr)
WO (1) WO2022018256A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722190B1 (fr) * 1994-07-05 1996-10-04 Sanofi Sa Derives de 1-benzyl-1,3-dihydro-2h-benzimidazol-2-one, leur preparation, les compositions pharmaceutique en contenant
US7589239B2 (en) * 2005-09-02 2009-09-15 Auspex Pharmaceuticals Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
WO2012174224A2 (fr) * 2011-06-17 2012-12-20 Calando Pharmaceuticals, Inc. Procédés d'administration de produits thérapeutiques à base d'acide nucléique
WO2016120432A1 (fr) * 2015-01-30 2016-08-04 Fundación Para La Investigación Médica Aplicada Composés et procédés pour traitement anticoagulant
WO2016173948A1 (fr) * 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Indazolopyrimidinones comme inhibiteurs de la fibrinolyse
US11278025B2 (en) * 2017-05-17 2022-03-22 The General Hospital Corporation Antibiotic compounds
CN111329851A (zh) * 2018-06-08 2020-06-26 中国医学科学院皮肤病医院 阿达帕林和抗增殖药物联合在制备预防或治疗血液系统肿瘤药物中的应用

Also Published As

Publication number Publication date
JP2024511910A (ja) 2024-03-18
EP4185281A1 (fr) 2023-05-31
CN116710080A (zh) 2023-09-05
US20230346727A1 (en) 2023-11-02
FR3112684A1 (fr) 2022-01-28
WO2022018256A1 (fr) 2022-01-27
CA3186258A1 (fr) 2022-01-27

Similar Documents

Publication Publication Date Title
MA37834A1 (fr) Analogues de pyridazine 1,4-disubstituée et procédés de traitement de troubles liés à une déficience en smn
MA38227A1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase
MA44721A (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA33886B1 (fr) Dérivés substitués d'acide carbamoylméthylamino-acétique utilisés comme nouveaux inhibiteurs de nep
CZ20014289A3 (cs) Nové pouľití sloučenin jako antibakteriálních činidel
MA33772B1 (fr) Dérivés d'acide carboxylique cyclique substitué par acylamino et leur utilisation en tant qu'agents pharmaceutiques
MA31894B1 (fr) Composes organiques
MA35348B1 (fr) 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk
MA30412B1 (fr) Composés Pharmaceutiques
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
TNSN04137A1 (fr) Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
TNSN07022A1 (fr) Derives de pyridine
TN2009000450A1 (fr) Derives de pyridine
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
NZ514981A (en) Renin inhibitors
MA29926B1 (fr) Derives de pyrazine
DE69731610D1 (de) Orale verabreichung wirksamer mengen von hyaluronsäure
MA35411B1 (fr) Nouvelle composition thérapeutique contenant de l'apomorphine comme principe actif
MA35286B1 (fr) Phényl-3-aza-bicyclo[3.1.0]hex-3-yl-méthanones et leur utilisation en tant que médicament
MA38330A1 (fr) Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre)

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220128

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4